MAPT and Alzheimer disease: In particular, a recent study of detection of p-tau231 in the CSF of patients with AD reported a high sensitivity of 85% and a specificity of 97% in separating AD from dementia with Lewy bodies and vascular dementia and indicated the appearance of p-tau231 in the early stages of pathology in patients with AD compared to other p-tau [4], reflecting the beneficial features of p-tau231 as a new biomarker for the early onset of AD pathology.